Protocol Number:
NCT02854436
Study Name:
An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)
Age Group:
Adult
Background Information:
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
See full details
Protocol Number:
NCT03834493
Study Name:
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
Age Group:
Adult
Background Information:
The purpose of this study is to test the safety and efficacy of Pembrolizumab, also known as KEYTRUDA®, or a placebo in combination with a hormone drug (Enzalutamide) for prostate cancer
See full details
Protocol Number:
NCT03834506
Study Name:
A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) (KEYNOTE-921)
Age Group:
Adult
Background Information:
The purpose of this study is to test the safety of the study drug, pembrolizumab, in combination with a chemotherapy plus a steroid on participants with mCRPC with disease progression after being treated with a NHA. The study will determine the safety and efficacy of pembrolizumab compared to placebo (a look-alike with no active ingredients) in combination with a chemotherapy and a steroid. Pembrolizumab (MK-3475), also known as KEYTRUDA®.
See full details
Protocol Number:
NCT02465060
Study Name:
NCI MATCH Molecular Analysis for Therapy Choice
Age Group:
Adult
Background Information:
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
See full details
Protocol Number:
NCT02693535
Study Name:
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Age Group:
Adult
Background Information:
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. The study provides approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies, catalogues the choice of genomic profiling test by clinical oncologists and aims to learn about the utility of registry data to develop hypotheses for additional clinical trials.
See full details
Protocol Number:
NCT03435640
Study Name:
A phase 1/2, open-label, multicenter study of the combination of NKTR-214 and Nivolumab or the combination of NKTR-214, Nivolumab and Ipilimumab in patients with select locally advanced or metastatic solid tumor malignancies (NEKTAR)
Age Group:
Adult
Background Information:
Patients will receive intratumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic administration of NKTR-214. After determination of the recommended Phase 2 dose (RP2D) of NKTR-262, NKTR-262 will be combined with NKTR-214 (Cohort A) and with NKTR-214 plus nivolumab (Cohort B). In the Phase 2 dose expansion portion, patients will be treated with NKTR-262 and NKTR-214 (doublet) or NKTR-262 and NKTR-214 plus nivolumab (triplet) in the relapsed/refractory setting and earlier lines of therapy.
See full details